BIOLASE, Inc.

Equities

BIOL

US0909117022

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
0.1762 ^USD	+4.88%		+21.85%	-84.30%

Apr. 01	Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating	MT
Mar. 22	Wall Street Set to Open Marginally Lower Friday Following Powell Speech, After Hitting Record Highs Thursday	MT

BIOLASE, Inc. Provides Revenue Guidance for the Fourth Quarter of 2021

January 10, 2022 at 06:30 am EST

BIOLASE, Inc. provided revenue guidance for the fourth Quarter of 2021. Revenue is expected to be in the range of $12.2 million to $12.5 million, up 44% to 47% over the fourth quarter 2020 results and up 20% to 23% over the fourth quarter 2019 pre-COVID results.

Latest news about BIOLASE, Inc.

Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating	Apr. 01	MT
Wall Street Set to Open Marginally Lower Friday Following Powell Speech, After Hitting Record Highs Thursday	Mar. 22	MT
US Stock Futures Flat Ahead of Powell Speech After Reaching Record Highs on Thursday	Mar. 22	MT
Top Premarket Gainers	Mar. 22	MT
Transcript : BIOLASE, Inc., Q4 2023 Earnings Call, Mar 21, 2024	Mar. 21
BIOLASE, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024	Mar. 21	CI
BIOLASE, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Biolase Prices $7 Million Public Offering	Feb. 13	MT
BIOLASE, Inc. Provides Earnings Guidance for the Full-Year 2023	Jan. 29	CI
BIOLASE, Inc. Provides Earnings Guidance for the Year 2024	Jan. 29	CI
Dr. Carol Gomez Summerhays Intends to Resign as Member of the Board of Directors of Biolase, Inc	Dec. 29	CI
BIOLASE, Inc. Successfully Concludes Waterlase iPlus All Tissue Laser Trial	Dec. 12	CI
Biolase, Inc. Enters into the Eleventh Amendment to Credit Agreement with SWK Funding LLC	Nov. 17	CI
BIOLASE, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Transcript : BIOLASE, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Earnings Flash (BIOL) BIOLASE Reports Q3 Revenue $10.9M, vs. Street Est of $13.2M	Nov. 09	MT
BIOLASE, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023	Nov. 09	CI
BIOLASE, Inc. Announces Study Performed by the Independent Mcguire Institute Confirms Positive 12 Month Clinical Outcomes for Biolase Repair(R) Perio Protocol	Nov. 08	CI
Biolase Closes Public Offering of 75,000 Units at $60.00 Each	23-09-19	MT
Sector Update: Health Care Stocks Rising Late Afternoon	23-09-14	MT
Sector Update: Health Care	23-09-14	MT
Top Midday Decliners	23-09-14	MT
Hotter-Than-Expected August Retail Sales Inflation Stifles US Equity Futures Pre-Bell	23-09-14	MT
Top Premarket Decliners	23-09-14	MT
Biolase Prices $4.5 Million Offering of Preferred Stock, Warrants	23-09-14	MT

Chart BIOLASE, Inc.

Duration

Period

More charts

Company Profile

BIOLASE, Inc. is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company's systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. It offers two categories of laser system products: Waterlase (all-tissue) systems and diode (soft-tissue) systems. The Company's all-tissue Waterlase dental laser systems consist of its flagship Waterlase iPlus, Waterlase Express, and Waterlase MDX. Its soft tissue diode laser systems consist of the Epic X, Epic Hygiene, Epic Q, and Epic 10 diode lasers that perform soft tissue, hygiene, cosmetic procedures, teeth whitening, and provide temporary pain relief. Epic X, and Epic 10 systems feature its 940 nanometer wavelength with patented pulse technology called ComfortPulse.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-12 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for BIOLASE, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.1762 USD

Average target price

1.633 USD

Spread / Average Target

+826.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
BIOLASE, INC.	-84.30%	5.86M
THERMO FISHER SCIENTIFIC	+8.07%	219B
DANAHER CORPORATION	+7.87%	185B
INTUITIVE SURGICAL, INC.	+12.75%	135B
SIEMENS HEALTHINEERS AG	-1.37%	62.21B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.88%	51.01B
EDWARDS LIFESCIENCES CORPORATION	+11.59%	51.28B
AGILENT TECHNOLOGIES, INC.	+2.71%	41.85B
GE HEALTHCARE TECHNOLOGIES INC.	+4.90%	37.02B
RESMED, INC.	+23.75%	31.27B

Other Advanced Medical Equipment & Technology